July 11, 2025
2 min watch
On this video, Jeff Yu, MD, MS, highlighted the attainable future instructions of atopic dermatitis like additional improvement of topical therapies, mixture therapies and discussions of illness remission.
Yu stated roflumilast will quickly be obtainable for the therapy of sufferers aged 2 to six years, which would be the newest topical approval for the therapy of AD outdoors of tacrolimus, pimecrolimus and crisaborole.
“I believe that we’re actually in a really thrilling time for AD nonetheless, and I do know we have been speaking about this for the previous few years, however I believe for the previous few years we had our first biologics, then we had Janus kinase inhibitors and that was actually thrilling. Now I believe we’re actually shifting on to the following stage of AD, so I am unable to wait to see what comes out within the subsequent 12 months,” stated Yu.
